Hélène Moore’s Post

Eli Lilly's recent announcement regarding the impressive efficacy of its weight-loss drug provides significant insights into the evolving landscape of diabetes and obesity management. The profound impact that tirzepatide has demonstrated—nearly eliminating the progression to type 2 diabetes among pre-diabetic, overweight individuals—highlights its potential as a cornerstone therapy amid growing concerns about medication adherence observed in competing treatments. As the healthcare market increasingly gravitates towards preventative measures, the robust outcomes from the long-duration trial suggest that Lilly could secure a competitive edge in the burgeoning obesity treatment sector. The strategic shift towards incorporating data that emphasizes both weight loss and the mitigation of associated comorbidities aligns well with evolving patient needs and physician practices, thereby solidifying the company's market position while addressing the complex interplay between obesity and diabetes. Additionally, with competitors like Novo Nordisk facing challenges in medication retention among users, Lilly's findings could foster greater trust and long-term commitment from patients and healthcare providers alike, propelling sustained demand for its offerings.

American College of Physicians Guideline on Pharmacologic Treatments for Diabetes: Key Points ·       ACP recommends adding an SGLT-2 inhibitor or GLP-1 agonist to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control (strong recommendation; high-certainty evidence) ·       Newer pharmacologic treatments of type 2 diabetes that reduced all-cause mortality compared with placebo or usual care were SGLT-2 inhibitors and GLP-1 agonists ·       ACP recommends against adding a dipeptidyl peptidase-4 (DPP-4) inhibitor to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control to reduce morbidity and all-cause mortality (strong recommendation; high-certainty evidence) With these latest recommendations in line, its imperative to discuss concepts like “all-cause mortality and morbidity” with patients. Its imperative that they are educated about these concepts beyond glycemic control which now can’t be the end target in diabetes management. It’s surprising to see that DDD-4 inhibitors don’t qualify to reduce the all-cause mortality though they bring down the sugars effectively. Its important that our patients know this and take an informed and mutual discussion with their physicians. In India, this may take time as the prices of GLP-1 agonists are still in four digits. In India, the price of a drug can significantly impact its prescription and usage. Affordability plays a crucial role, especially in a country where healthcare expenses can be a major concern for many people. Time will reveal how the prescription of these drugs will unfold especially with the advent of more affordable medications. https://lnkd.in/gAYRxMuT #diabetescontrol #allcausemortality #antidiabeticdrugs #patientawareness #patienteducation #americancollegeofphysicians #ACP

Severe #digestivehealth side effects are a top reason for abandoning #GLP1 medication treatment for obesity, experienced by 40-70% of patients. GLP-1 agonists work in part by delaying gastric emptying or how fast food leaves the body, which is why these side effects are so common.  But the lawsuits referenced in this USA Today article indicate that side effects are not consistently being communicated well and/or effective access to treatment made available. Wraparound support by a #gastroenterologist can make a huge difference in accurately addressing these symptoms or medical conditions and keeping people on GLP1 therapy to gain the full value of the medication relative to the price. The problem is often the wait to get an appointment with a gastroenterologist, which can be months in many parts of the country. These symptoms can’t wait months. There are an estimated 15,000 gastroenterologists in the US. More than half of them are over age 55 and a retirement wave is cresting. Only 400-500 new gastroenterology fellows graduate each year. And demand for the colonoscopy & endoscopy procedures they perform is increasing with the screening age for colorectal cancer now lowered to 45. Add in physician burnout, which will lead to reduced hours or leaving practice, and we have an access crisis brewing. GLP-1 patients need immediate access to GI-specialized care and support through this journey, not only to manage emergent or persistent side effects but to also monitor them for more serious complications like gastroparesis, bowel obstruction, pancreatic, or biliary issues. A GI-specialized medical team like ours at Oshi Health can help manage symptoms through the critical dose-increase phase and provide fast access for more significant symptoms to support diagnosis and treatment. The far-reaching effects of GLP-1 medications are only just beginning to come into focus. Articles like this show the severity of suffering and avoidable surgeries, adding yet another reason for scaling access to virtual multidisciplinary GI care covered by insurance. #weightloss #virtualcare #obesity https://lnkd.in/eXFFcrpf

Is obesity a disease? This has been a debatable question for over a decade now, and with the discovery of GLP-1 medications, it is being pushed again, but if you look at why it is being pushed, I think we are being used as pawns for the pharmaceutical companies again. Much like their push for pain to be a vital sign, in an effort to increase sales of OxyContin, I believe they are doing the same with obesity to increase sales of GLP-1 medications. Once you take a broad view of the big picture, GLP-1s have a lot of problems, and are not the solution we are being lead to believe they are. And we have taken all focus away from ultra processed foods, behavior changes, exercise, and everything else that research has supported for the past 50 years. While this was published 10 years ago, the arguments have not changed. The perception has been clouded by those who wish to profit, but as medical professionals, it is our job to follow science. https://lnkd.in/gbxBZWxF

Only put off until tomorrow what you are willing to die having left undone. FDA Approves J&J's Tremfya for Ulcerative Colitis & Novo Nordisk’s Obesity Pill Shows Promising Results This week, the FDA gave its approval for J&J's JNJ Tremfya to be used in the treatment of ulcerative colitis, an inflammatory bowel disease condition. This is a significant milestone in the healthcare sector as it provides a new option for patients suffering from this condition. In another breakthrough, Novo Nordisk's NVO oral obesity pill, amycretin, demonstrated faster weight loss compared to its blockbuster weekly injection, Wegovy (semaglutide). The positive results came from a comprehensive 12-week phase I study presented at the European Association. As an experienced Investment Advisor, I would like to emphasize the importance of staying informed and taking advantage of opportunities in the healthcare sector. Investing in companies that are making significant advancements in medical treatments can lead to substantial returns. Don't miss out on the potential growth and profits that investing in healthcare can offer. Act now to ensure a healthy future for yourself, your family, and your finances. Whether it's utilizing your Health Savings Account or exploring other investment options, seize the moment and take advantage of the exciting developments in the industry. #HSA #Investing #Healthcare #Health #Family #Wellness 💪💰📈✨👨⚕️👩⚕️

Innovative Study Reveals Key Insights into Diabetes Management A recent study published in JAMA reveals significant findings about diabetes management. The study involved 3,000 participants over five years and explored the effectiveness of different treatment regimens. The group receiving a combination of medication and intensive lifestyle changes achieved the most significant reduction in HbA1c levels and reported fewer complications. These findings could lead to new treatment protocols and easier regulatory approval for emerging diabetes therapies. Healthcare providers may need to reconsider current treatment practices and emphasize personalized treatment plans. The study's implications include the need for a holistic approach to diabetes management and the potential for quicker market access for innovative therapies. Ultimately, the research aims to improve patient outcomes and lead to healthcare reforms. For more details please click the link! https://lnkd.in/dwWjCkuX #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

📣Pay attention folks!📣 A triple agonist medication for obesity and diabetes (currently there is only one dual-agonist available- Mounjaro) is now in phase II of clinical trials! #Retatrutide will most likely be available in a year. Dr. Alexander Williams told me to expect this years ago, and many other providers and pharmacists have been anticipating these new medications to help better treat patients. Looking at this trial data…the amount of fat that these medications can eliminate from the liver is extraordinary. Imagine the amount of heart and kidney disease (whether primary or secondary) that these medications will help prevent as well! Eli Lilly and Company #DiabetesMedications #GLP #GIP #Glucagon #ObesityMedications #WeightLossDrugs

🚀 Exciting News Alert! 🚀 Beckley Psytech reports positive initial findings from their Phase IIa clinical study (NCT05660642) of BPL-003 (5-MeO-DMT) for Treatment Resistant Depression (TRD). BPL-003 is benzoate salt formulation of 5-MeO-DMT (Mebufotenin), administered intranasally. In this open-label study, a single 10mg dose of BPL-003 was well-tolerated and demonstrated rapid, durable efficacy in patients with TRD. Key highlights include: ·      Rapid antidepressant response observed in 55% of patients the day after dosing. ·      55% of patients in remission from depression at day 29 and 45% at day 85 post-dosing. “Acute effects were resolved and patients were deemed dischargeable within an average time of less than 2 hours. This signals the potential for a shorter treatment duration and reduced resource burden for healthcare systems compared to other psychedelic treatments currently in development.” #psychedelics #clinicaltrials #mentalhealth #treatmentresistentdepression

Medicare is considering the inclusion of obesity drugs in its list of covered medications, following promising studies indicating these drugs could reduce cardiovascular risks by up to 20%. As a company that owns and manages medical buildings, this development brings up numerous considerations. How this could alter the requirements for the physical space of both new and existing healthcare buildings. We are curious about the timeline for these changes and the current volume of cardiac procedures performed in Ambulatory Surgical Centers (ASCs). Additionally, we are considering the ideal size and layout for a medical center in this evolving context. If Medicare decides to cover these obesity treatments, could this increase the demand for life science buildings dedicated to pharmaceutical purposes? We understand that changes in government policies and healthcare systems can be slow. However, we aim to stay informed and prepare for how these potential shifts could influence our clients' needs.

Interesting article on weight loss drugs and muscle mass and how to combat!